Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
Valuation ratio | Description | The company |
---|---|---|
P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Illumina Inc. P/E ratio increased from Q1 2021 to Q2 2021 but then decreased significantly from Q2 2021 to Q3 2021. |
P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Illumina Inc. P/S ratio increased from Q1 2021 to Q2 2021 but then decreased significantly from Q2 2021 to Q3 2021. |
P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | Illumina Inc. P/BV ratio increased from Q1 2021 to Q2 2021 but then decreased significantly from Q2 2021 to Q3 2021. |
Price to Earnings (P/E)
Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | 156,300,000 | 146,700,000 | 146,000,000 | 145,900,000 | 146,000,000 | 146,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 146,000,000 | 146,000,000 | 146,000,000 | 146,300,000 | 146,900,000 | 146,600,000 | 147,200,000 | |||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
Net income attributable to Illumina stockholders (in millions) | 317) | 185) | 147) | 257) | 179) | 47) | 173) | 239) | 234) | 296) | 233) | 210) | 199) | 209) | 208) | 68) | 163) | 128) | 367) | 124) | 129) | 120) | 90) | |||||||
Earnings per share (EPS)2 | 5.80 | 5.24 | 4.32 | 4.50 | 4.37 | 4.75 | 6.41 | 6.82 | 6.62 | 6.38 | 5.79 | 5.62 | 4.65 | 4.41 | 3.86 | 4.94 | 5.35 | 5.12 | 5.07 | 3.16 | 0.00 | 0.00 | 0.00 | |||||||
Share price1, 3 | 408.14 | 497.24 | 405.54 | 494.24 | 292.70 | 355.66 | 305.88 | 296.00 | 290.64 | 299.38 | 314.04 | 292.20 | 289.50 | 324.36 | 231.19 | 220.44 | 204.85 | 198.46 | 187.14 | 164.46 | 137.70 | 166.92 | 141.76 | |||||||
Valuation Ratio | ||||||||||||||||||||||||||||||
P/E ratio4 | 70.41 | 94.98 | 93.98 | 109.92 | 66.98 | 74.93 | 47.73 | 43.43 | 43.91 | 46.92 | 54.25 | 52.00 | 62.22 | 73.58 | 59.94 | 44.63 | 38.26 | 38.75 | 36.92 | 52.01 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
P/E Ratio, Competitors5 | ||||||||||||||||||||||||||||||
AbbVie Inc. | 27.34 | 30.62 | 39.63 | 40.17 | 22.60 | 23.92 | 14.70 | 17.82 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Amgen Inc. | 21.91 | 22.56 | 19.20 | 18.82 | 17.25 | 19.97 | 17.70 | 17.07 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Bristol-Myers Squibb Co. | — | — | — | — | — | — | 144.77 | 41.99 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Danaher Corp. | 38.81 | 37.87 | 39.26 | 44.49 | 46.61 | 41.91 | 35.88 | 38.34 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Eli Lilly & Co. | 40.07 | 40.34 | 28.77 | 31.95 | 22.54 | 25.59 | 26.56 | 16.19 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Gilead Sciences Inc. | 11.44 | 16.83 | 277.25 | 641.48 | 59.19 | — | 19.58 | 16.45 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Johnson & Johnson | 23.98 | 25.51 | 28.35 | 28.92 | 22.51 | 25.68 | 23.06 | 25.99 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Merck & Co. Inc. | 28.65 | 34.23 | 28.00 | 26.72 | 17.67 | 19.70 | 19.18 | 20.60 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Moderna Inc. | 16.31 | 48.08 | 107.74 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Pfizer Inc. | 14.03 | 20.05 | 20.15 | 19.62 | 25.36 | 14.99 | 13.04 | 11.63 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 9.96 | 10.38 | 13.27 | 15.09 | 19.91 | 22.27 | 28.35 | 19.86 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Thermo Fisher Scientific Inc. | 29.43 | 24.63 | 23.23 | 27.89 | 38.43 | 44.19 | 35.50 | 33.36 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Data adjusted for splits and stock dividends.
2 Q3 2021 Calculation
EPS
= (Net income attributable to Illumina stockholdersQ3 2021
+ Net income attributable to Illumina stockholdersQ2 2021
+ Net income attributable to Illumina stockholdersQ1 2021
+ Net income attributable to Illumina stockholdersQ4 2020)
÷ No. shares of common stock outstanding
= (317,000,000 + 185,000,000 + 147,000,000 + 257,000,000)
÷ 156,300,000 = 5.80
3 Closing price as at the filing date of Illumina Inc. Quarterly or Annual Report.
4 Q3 2021 Calculation
P/E ratio = Share price ÷ EPS
= 408.14 ÷ 5.80 = 70.41
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Illumina Inc. P/E ratio increased from Q1 2021 to Q2 2021 but then decreased significantly from Q2 2021 to Q3 2021. |
Price to Operating Profit (P/OP)
Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | 156,300,000 | 146,700,000 | 146,000,000 | 145,900,000 | 146,000,000 | 146,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 146,000,000 | 146,000,000 | 146,000,000 | 146,300,000 | 146,900,000 | 146,600,000 | 147,200,000 | |||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
Income (loss) from operations (in millions) | (545) | 187) | 193) | 133) | 162) | 96) | 189) | 268) | 308) | 205) | 204) | 197) | 241) | 227) | 218) | 230) | 181) | 143) | 52) | 143) | 161) | 162) | 121) | |||||||
Operating profit per share2 | -0.20 | 4.60 | 4.00 | 3.98 | 4.90 | 5.90 | 6.60 | 6.70 | 6.22 | 5.76 | 5.91 | 6.01 | 6.23 | 5.82 | 5.25 | 4.12 | 3.55 | 3.42 | 3.55 | 4.01 | 0.00 | 0.00 | 0.00 | |||||||
Share price1, 3 | 408.14 | 497.24 | 405.54 | 494.24 | 292.70 | 355.66 | 305.88 | 296.00 | 290.64 | 299.38 | 314.04 | 292.20 | 289.50 | 324.36 | 231.19 | 220.44 | 204.85 | 198.46 | 187.14 | 164.46 | 137.70 | 166.92 | 141.76 | |||||||
Valuation Ratio | ||||||||||||||||||||||||||||||
P/OP ratio4 | — | 108.07 | 101.39 | 124.33 | 59.77 | 60.31 | 46.36 | 44.17 | 46.74 | 51.96 | 53.12 | 48.64 | 46.46 | 55.70 | 44.02 | 53.47 | 57.62 | 58.10 | 52.79 | 40.99 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
P/OP Ratio, Competitors5 | ||||||||||||||||||||||||||||||
AbbVie Inc. | 12.41 | 13.12 | 17.23 | 16.32 | 14.42 | 15.23 | 9.13 | 10.82 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Amgen Inc. | 16.73 | 17.48 | 15.26 | 14.96 | 13.82 | 15.84 | 14.22 | 13.84 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Bristol-Myers Squibb Co. | — | — | — | — | 39.45 | 33.97 | 27.33 | 24.42 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Danaher Corp. | 32.12 | 30.83 | 32.62 | 36.91 | 46.28 | 43.09 | 35.22 | 34.47 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Eli Lilly & Co. | 37.21 | 42.01 | 31.17 | 32.66 | 22.98 | 25.58 | 24.82 | 27.08 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Gilead Sciences Inc. | 7.27 | 8.88 | 18.31 | 19.38 | 29.86 | — | 21.83 | 20.66 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Johnson & Johnson | 18.99 | 20.14 | 21.12 | 21.84 | 19.46 | 19.66 | 18.67 | 19.83 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Merck & Co. Inc. | 30.71 | 38.03 | 30.14 | 23.89 | 16.00 | 17.23 | 15.88 | 17.47 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Moderna Inc. | 15.13 | 44.01 | 101.69 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Pfizer Inc. | 16.37 | 19.83 | 22.85 | 23.12 | 22.27 | 22.17 | 17.42 | 14.36 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 9.32 | 9.65 | 13.32 | 14.82 | 20.36 | 23.98 | 26.60 | 19.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Thermo Fisher Scientific Inc. | 23.87 | 19.77 | 18.53 | 22.81 | 31.49 | 36.59 | 28.44 | 26.84 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Data adjusted for splits and stock dividends.
2 Q3 2021 Calculation
Operating profit per share
= (Income (loss) from operationsQ3 2021
+ Income (loss) from operationsQ2 2021
+ Income (loss) from operationsQ1 2021
+ Income (loss) from operationsQ4 2020)
÷ No. shares of common stock outstanding
= (-545,000,000 + 187,000,000 + 193,000,000 + 133,000,000)
÷ 156,300,000 = -0.20
3 Closing price as at the filing date of Illumina Inc. Quarterly or Annual Report.
4 Q3 2021 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 408.14 ÷ -0.20 = —
5 Click competitor name to see calculations.
Price to Sales (P/S)
Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | 156,300,000 | 146,700,000 | 146,000,000 | 145,900,000 | 146,000,000 | 146,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 146,000,000 | 146,000,000 | 146,000,000 | 146,300,000 | 146,900,000 | 146,600,000 | 147,200,000 | |||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
Revenue (in millions) | 1,108) | 1,126) | 1,093) | 953) | 794) | 633) | 859) | 952) | 907) | 838) | 846) | 868) | 853) | 830) | 782) | 778) | 714) | 662) | 598) | 619) | 607) | 600) | 572) | |||||||
Sales per share2 | 27.38 | 27.03 | 23.79 | 22.20 | 22.18 | 22.95 | 24.19 | 24.10 | 23.53 | 23.16 | 23.11 | 22.67 | 22.06 | 21.12 | 19.97 | 18.72 | 17.76 | 17.03 | 16.61 | 16.39 | 0.00 | 0.00 | 0.00 | |||||||
Share price1, 3 | 408.14 | 497.24 | 405.54 | 494.24 | 292.70 | 355.66 | 305.88 | 296.00 | 290.64 | 299.38 | 314.04 | 292.20 | 289.50 | 324.36 | 231.19 | 220.44 | 204.85 | 198.46 | 187.14 | 164.46 | 137.70 | 166.92 | 141.76 | |||||||
Valuation Ratio | ||||||||||||||||||||||||||||||
P/S ratio4 | 14.90 | 18.39 | 17.05 | 22.26 | 13.20 | 15.50 | 12.64 | 12.28 | 12.35 | 12.92 | 13.59 | 12.89 | 13.12 | 15.36 | 11.58 | 11.77 | 11.53 | 11.65 | 11.27 | 10.03 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
P/S Ratio, Competitors5 | ||||||||||||||||||||||||||||||
AbbVie Inc. | 3.73 | 3.80 | 4.07 | 4.05 | 4.10 | 4.59 | 3.64 | 4.22 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Amgen Inc. | 5.04 | 5.37 | 5.68 | 5.64 | 5.33 | 6.30 | 5.96 | 6.03 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Bristol-Myers Squibb Co. | 2.85 | 3.44 | 3.28 | 3.16 | 3.66 | 3.97 | 4.45 | 5.52 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Danaher Corp. | 7.91 | 7.72 | 7.27 | 7.01 | 8.15 | 7.48 | 6.34 | 6.29 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Eli Lilly & Co. | 8.62 | 9.16 | 6.88 | 8.06 | 5.41 | 6.26 | 6.36 | 6.03 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Gilead Sciences Inc. | 3.11 | 3.30 | 3.31 | 3.24 | 3.29 | 3.95 | 4.34 | 4.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Johnson & Johnson | 4.69 | 5.08 | 5.09 | 5.15 | 4.73 | 4.84 | 4.78 | 4.79 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Merck & Co. Inc. | 4.32 | 4.05 | 4.23 | 3.93 | 4.30 | 4.38 | 4.05 | 4.33 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Moderna Inc. | 10.53 | 27.41 | 33.34 | 309.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Pfizer Inc. | 4.04 | 4.78 | 4.84 | 4.50 | 4.71 | 4.69 | 4.21 | 3.66 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 5.14 | 5.20 | 5.78 | 6.24 | 7.62 | 8.31 | 8.10 | 5.34 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Thermo Fisher Scientific Inc. | 6.45 | 5.54 | 5.13 | 5.52 | 6.58 | 6.24 | 5.08 | 4.83 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Data adjusted for splits and stock dividends.
2 Q3 2021 Calculation
Sales per share
= (RevenueQ3 2021
+ RevenueQ2 2021
+ RevenueQ1 2021
+ RevenueQ4 2020)
÷ No. shares of common stock outstanding
= (1,108,000,000 + 1,126,000,000 + 1,093,000,000 + 953,000,000)
÷ 156,300,000 = 27.38
3 Closing price as at the filing date of Illumina Inc. Quarterly or Annual Report.
4 Q3 2021 Calculation
P/S ratio = Share price ÷ Sales per share
= 408.14 ÷ 27.38 = 14.90
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Illumina Inc. P/S ratio increased from Q1 2021 to Q2 2021 but then decreased significantly from Q2 2021 to Q3 2021. |
Price to Book Value (P/BV)
Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | 156,300,000 | 146,700,000 | 146,000,000 | 145,900,000 | 146,000,000 | 146,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 147,000,000 | 146,000,000 | 146,000,000 | 146,000,000 | 146,300,000 | 146,900,000 | 146,600,000 | 147,200,000 | |||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
Total Illumina stockholders’ equity (in millions) | 10,593) | 5,180) | 4,922) | 4,694) | 4,700) | 4,563) | 4,635) | 4,613) | 4,439) | 4,332) | 3,985) | 3,758) | 3,503) | 3,257) | 3,008) | 2,749) | 2,855) | 2,715) | 2,551) | 2,197) | 2,240) | 2,056) | 1,991) | |||||||
Book value per share (BVPS)2 | 67.77 | 35.31 | 33.71 | 32.17 | 32.19 | 31.25 | 31.53 | 31.38 | 30.20 | 29.47 | 27.11 | 25.56 | 23.83 | 22.16 | 20.46 | 18.70 | 19.55 | 18.60 | 17.47 | 15.02 | 15.25 | 14.02 | 13.53 | |||||||
Share price1, 3 | 408.14 | 497.24 | 405.54 | 494.24 | 292.70 | 355.66 | 305.88 | 296.00 | 290.64 | 299.38 | 314.04 | 292.20 | 289.50 | 324.36 | 231.19 | 220.44 | 204.85 | 198.46 | 187.14 | 164.46 | 137.70 | 166.92 | 141.76 | |||||||
Valuation Ratio | ||||||||||||||||||||||||||||||
P/BV ratio4 | 6.02 | 14.08 | 12.03 | 15.36 | 9.09 | 11.38 | 9.70 | 9.43 | 9.62 | 10.16 | 11.58 | 11.43 | 12.15 | 14.64 | 11.30 | 11.79 | 10.48 | 10.67 | 10.71 | 10.95 | 9.03 | 11.90 | 10.48 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
P/BV Ratio, Competitors5 | ||||||||||||||||||||||||||||||
AbbVie Inc. | 15.20 | 16.23 | 14.91 | 14.18 | 10.93 | 11.31 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Amgen Inc. | 14.95 | 15.72 | 14.57 | 14.53 | 11.57 | 13.67 | 14.33 | 13.84 | 11.47 | 10.37 | 9.92 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Bristol-Myers Squibb Co. | 3.48 | 4.15 | 3.73 | 3.55 | 2.87 | 2.82 | 2.77 | 2.80 | 5.30 | 4.63 | 4.91 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Danaher Corp. | 5.11 | 4.82 | 4.46 | 3.93 | 4.38 | 3.90 | 3.68 | 3.72 | 3.02 | 3.19 | 2.88 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Eli Lilly & Co. | 30.85 | 38.00 | 25.41 | 35.07 | 26.02 | 35.12 | 47.73 | 51.67 | 31.28 | 39.03 | 46.37 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Gilead Sciences Inc. | 3.94 | 4.41 | 4.40 | 4.33 | 4.30 | 4.79 | 4.40 | 3.93 | 4.02 | 3.58 | 3.83 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Johnson & Johnson | 6.10 | 6.51 | 6.51 | 6.72 | 5.93 | 6.19 | 6.46 | 6.61 | 5.84 | 5.78 | 6.39 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Merck & Co. Inc. | 5.76 | 5.73 | 7.30 | 7.46 | 6.97 | 7.47 | 7.43 | 7.83 | 7.87 | 7.82 | 7.31 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Moderna Inc. | 11.37 | 25.06 | 16.79 | 24.16 | 9.67 | 9.88 | 12.03 | 8.21 | 4.29 | 3.25 | 5.29 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Pfizer Inc. | 3.69 | 3.78 | 3.27 | 2.98 | 3.10 | 3.31 | 3.16 | 3.00 | 3.14 | 3.42 | 3.84 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 4.04 | 4.26 | 4.44 | 4.81 | 6.21 | 7.34 | 5.33 | 3.79 | 3.48 | 3.38 | 3.74 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Thermo Fisher Scientific Inc. | 6.51 | 5.75 | 5.25 | 5.15 | 5.89 | 5.48 | 4.56 | 4.16 | 4.15 | 3.83 | 4.02 | — | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Data adjusted for splits and stock dividends.
2 Q3 2021 Calculation
BVPS = Total Illumina stockholders’ equity ÷ No. shares of common stock outstanding
= 10,593,000,000 ÷ 156,300,000 = 67.77
3 Closing price as at the filing date of Illumina Inc. Quarterly or Annual Report.
4 Q3 2021 Calculation
P/BV ratio = Share price ÷ BVPS
= 408.14 ÷ 67.77 = 6.02
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | Illumina Inc. P/BV ratio increased from Q1 2021 to Q2 2021 but then decreased significantly from Q2 2021 to Q3 2021. |